Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof

A device and method of using the device to detect the presence and composition of clots and other target objects in a circulatory vessel of a living subject is described. In particular, devices and methods of detecting the presence and composition of clots and other target objects in a circulatory vessel of a living subject using in vivo photoacoustic flow cytometry techniques is described.

ABSTRACT

The present disclosure provides compositions and methods for selectively killing senescent cells, wherein the composition comprises a compound of Formula (I) or a compound of Formula (II). The selective killing of senescent cells may delay aging and/or treat age-related disorders.

CLAIMS

1. The compound of the formula:
BCL-L-E3 wherein, BCL is a protein targeting unit which binds to one or more anti-apoptotic Bcl-2 family proteins; E3 is an E3 ubiquitin ligase binding unit which binds to the CRBN or VHL E3 ubiquitin ligase; and L is a linker unit with two ends, each of which covalently links to one of BCL and E3 through one or more of the following functional groups: alkyl, branched alkyl, ether, thioether, ester, amine, amide, carbamate, carbamide, sulfone, aryl, heteroaryl, cycloalkyl, or heterocycle; wherein the linker comprises two ends, wherein each of the two ends are the same or different; wherein the linker unit comprises a length of 1-30 atoms, and wherein the compound has the following chemical structure: where R1 is NO2 or SO2CF3; where R2 is one of the following: where R3 is one of the following: where R4 is one of the following, wherein the bond between R4 and the remainder of BCL is indicated by a and the bond between R4 and L is indicated by β: where E3 has one of the following structures: where R6 and R7 are both  or R6 is  and R7 is H.

PATENT INFORMATION


Interested in this Technology?

The technologies listed here are available for licensing or for developmental partnership.
Please contact us if you have any questions, or if you would like further information on these or other upcoming BioVentures technologies.

Contact